Bicara Therapeutics Inc. (BCAX)
NASDAQ: BCAX · Real-Time Price · USD
8.71
-0.10 (-1.14%)
Jun 27, 2025, 4:00 PM - Market closed
Bicara Therapeutics Stock Forecast
Stock Price Forecast
According to 6 professional analysts, the 12-month price target for Bicara Therapeutics stock ranges from a low of $8.00 to a high of $47. The average analyst price target of $29.17 forecasts a 234.90% increase in the stock price over the next year.
Price Target: $29.17 (+234.90%)
Analyst Consensus: Strong Buy
* Price targets were last updated on May 23, 2025.
Analyst Ratings
The average analyst rating for Bicara Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 2 | 3 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 1 | 1 |
| Sell | 0 | 0 | 0 | 1 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 6 | 6 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Wells Fargo | Sell → Hold Upgrades $8 | Sell → Hold | Upgrades | $8 | -8.15% | May 23, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $44 → $41 | Strong Buy | Maintains | $44 → $41 | +370.72% | May 16, 2025 |
| Wells Fargo | Wells Fargo | Sell Initiates $8 | Sell | Initiates | $8 | -8.15% | Apr 17, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $45 → $44 | Strong Buy | Maintains | $45 → $44 | +405.17% | Apr 7, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $13 | Buy | Reiterates | $13 | +49.37% | Mar 13, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-2.47
from -4.05
EPS Next Year
-2.79
from -2.47
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | n/a | n/a | n/a |
| Avg | n/a | n/a | n/a |
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -2.05 | -1.89 | -2.08 |
| Avg | -2.47 | -2.79 | -2.88 |
| Low | -2.84 | -3.68 | -4.31 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.